Immunoassay for the Simultaneous Detection of Functional Antibodies against Multiple Serotypes of <em>Streptococcus pneumoniae</em> and Other Bacteria Types
Simple and Rapid Loop-Mediated Isothermal Amplification (LAMP)-based Assay for <em>Mycoplasma pneumoniae</em> Detection
Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences
Monoclonal Antibodies Against Bacillus Anthracis Antigens
Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva
Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development
Human influenza A is one of two influenza virus types that cause seasonal epidemics of disease (known as flu season) almost every winter in the United States. Influenza A viruses are the only influenza viruses known to cause flu pandemics (i.e., global epidemics of flu disease). (Source.)
Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development
Influenza A and B viruses can cause seasonal flu epidemics ― commonly known as the “flu season” ― and infect the nose, throat, eyes, and lungs in humans. Typically, flu seasons that are dominated by influenza A (H3N2) virus activity have higher associated hospitalizations and deaths in at-risk groups, such as people ages 65 and older and young children. Influenza A (H3N2) virus can also cause respiratory disease in animals, such as canines and swine.
Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine
Polio is a disabling and potentially fatal infectious disease. Sabin Oral Poliovirus Vaccine (OPV) and Salk Inactivated Poliovirus Vaccine (IPV) have been crucial in the global poliovirus eradication efforts and substantial decrease in disease incidence rates. However, recent findings showed that Sabin OPV strains, due to their genetic instability, may revert to virulence and spread among communities, resulting in circulating vaccine-derived poliovirus (cVDPV). Salk IPV, which is made by inactivating live poliovirus,
LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression
This technology includes the use of LZK and DLK inhibitors to be used for the treatment of head and neck squamous cell carcinoma (HNSCC) or lung squamous cell carcinoma (LSCC). Specifically, we demonstrate that inhibitors that can be repurposed to target LZK suppresses LZK kinase-dependent stabilization of MYC and activation of the PI3K/AKT pathway. In vivo preclinical cell line xenograft mouse model demonstrates that targeting LZK will suppress tumor growth. We also demonstrate that several additional compounds potently inhibit LZK and could serve as new therapeutic modalities.